IP Library Granted Patent US 8,106,036
Granted Patent B2
US 8,106,036 · App. 12/634,455 · Granted Jan 31, 2012

Pharmaceutical compositions-4

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,106,036
App. No.
12/634,455
Granted
Jan 31, 2012
Kind
B2
Abstract

The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Claims (15)

1. A formulation comprising one or more excipients and a compound having the structure

wherein

R 1 , R 2 , R 4 and R 10 independently are —OH, an ester or an ether;

R 3 is —H, —OH, an ester, an ether or halogen;

R 5 is —CH 3 or —CH 2 OH;

R 6 is —H, —CH 3 or —CH 2 OH;

and R 8 is —CH 2 — or, —CH(R 10 )— or.

2. The formulation of claim 1 wherein R 1 , R 2 and R 4 are —OH or an ester and R 3 is —OH, an ester or —Br.

3. The formulation of claim 2 wherein R 5 is —CH 3 .

4. The formulation of claim 3 wherein R 6 is —H or —CH 3 .

5. The formulation of claim 1 wherein the compound has the structure

6. The formulation of claim 5 wherein the compound has the structure

7. The formulation of claim 6 wherein R 1 , R 2 and R 4 are —OH and R 3 is —OH or —Br.

8. The formulation of claim 1 wherein the formulation is an oral formulation.

9. The formulation of claim 7 wherein the formulation is an oral formulation.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, INC.
To: NEURMEDIX, LLC
Reel/Frame 057116/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, INC.
To: BIOVIE INC.
Reel/Frame 057116/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, LLC
To: NEURMEDIX, INC.
Reel/Frame 057116/0362 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2018
From: RESERVA, LLC
To: NEURMEDIX, INC
Reel/Frame 047068/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2018
From: HARBOR THERAPEUTICS, INC.
To: RESERVA, LLC
Reel/Frame 046828/0014 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2018
From: HARBOR DIVERSIFIED, INC.
To: HARBOR THERAPEUTICS, INC.
Reel/Frame 046629/0331 →
CHANGE OF NAME Recorded Nov 2, 2012
From: HARBOR BIOSCIENCES, INC.
To: HARBOR DIVERSIFIED, INC.
Reel/Frame 029227/0929 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2010
From: FRINCKE, JAMES M.
To: HARBOR BIOSCIENCES, INC.
Reel/Frame 024237/0571 →
CHANGE OF NAME Recorded Mar 11, 2010
From: HOLLIS-EDEN PHARMACEUTICALS, INC.
To: HARBOR BIOSCIENCES, INC.
Reel/Frame 024066/0325 →